Open AccessThis article is
- freely available
Circulating Tumor Cells in Prostate Cancer
Institute of Urology, University of Southern California, 1441 Eastlake Avenue, Suite 7416, Los Angeles, CA 90033, USA
Department of Surgery, University of Southern California, 1520 San Pablo Street, HCT 4300, Los Angeles, CA 90033, USA
Department of Internal Medicine and Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, 1441 Eastlake Avenue, Suite 3440, Los Angeles, CA 90033, USA
* Author to whom correspondence should be addressed.
Received: 25 September 2013; in revised form: 20 November 2013 / Accepted: 25 November 2013 / Published: 4 December 2013
Abstract: Circulating tumor cells (CTCs) can provide a non-invasive, repeatable snapshot of an individual patient’s tumor. In prostate cancer, CTC enumeration has been extensively studied and validated as a prognostic tool and has received FDA clearance for use in monitoring advanced disease. More recently, CTC analysis has been shifting from enumeration to more sophisticated molecular characterization of captured cells, which serve as a “liquid biopsy” of the tumor, reflecting molecular changes in an individual’s malignancy over time. Here we will review the main CTC studies in advanced and localized prostate cancer, highlighting the important gains as well as the challenges posed by various approaches, and their implications for advancing prostate cancer management.
Keywords: circulating tumor cell; prostate cancer; personalized medicine
Citations to this Article
Cite This Article
MDPI and ACS Style
Hu, B.; Rochefort, H.; Goldkorn, A. Circulating Tumor Cells in Prostate Cancer. Cancers 2013, 5, 1676-1690.
Hu B, Rochefort H, Goldkorn A. Circulating Tumor Cells in Prostate Cancer. Cancers. 2013; 5(4):1676-1690.
Hu, Brian; Rochefort, Holly; Goldkorn, Amir. 2013. "Circulating Tumor Cells in Prostate Cancer." Cancers 5, no. 4: 1676-1690.